

Status: Currently Official on 15-Feb-2025
 Official Date: Official as of 01-Aug-2018
 Document Type: USP Monographs
 DocId: GUID-7449DC06-7A1C-4862-BFF3-0166B2235825_6_en-US
 DOI: https://doi.org/10.31003/USPNF_M54025_06_01
 DOI Ref: z4t2j

© 2025 USPC
 Do not distribute

Miconazole Nitrate Topical Powder

DEFINITION

Miconazole Nitrate Topical Powder contains NLT 90.0% and NMT 110.0% of the labeled amount of miconazole nitrate ($C_{18}H_{14}Cl_4N_2O \cdot HNO_3$).

IDENTIFICATION

• A.

Sample: Transfer nominally 100 mg of miconazole nitrate from Topical Powder to a 50-mL beaker, disperse in 40 mL of [methanol](#), and mix for a minimum of 5 min. Allow to settle for 5–10 min and filter into a 100-mL beaker. Evaporate on a steam bath or by a rotary evaporator to dryness. Dry the residue at 105° for 10 min.

Acceptance criteria: The IR absorption spectrum of a potassium bromide dispersion of the residue obtained from the *Sample* exhibits maxima only at the same wavelengths as that of a similar preparation of [USP Miconazole Nitrate RS](#).

• B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Buffer: 4.6 g/L of [dibasic potassium phosphate trihydrate](#) in [water](#). Adjust with [phosphoric acid](#) to a pH of 7.5.

Solution A: [Acetonitrile](#) and Buffer (65:35)

Solution B: [Acetonitrile](#)

Solution C: [Acetonitrile](#), [water](#), and [phosphoric acid](#) (50:50:0.05)

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)	Solution C (%)	Flow rate (mL/min)
0	100	0	0	1.0
17.0	86	14	0	1.0
17.1	0	0	100	3.0
28.0	0	0	100	3.0
28.1	100	0	0	2.0
38.0	100	0	0	2.0
38.1	100	0	0	1.0
40	100	0	0	1.0

Diluent: [Acetonitrile](#) and [water](#) (50:50)

Standard stock solution: 2 mg/mL of [USP Miconazole Nitrate RS](#) in *Diluent*. Sonication may be needed to aid dissolution.

Standard solution: 0.2 mg/mL of [USP Miconazole Nitrate RS](#) in *Diluent* from the *Standard stock solution*

Sample solution: Nominally 0.2 mg/mL of miconazole nitrate in *Diluent* prepared as follows. Transfer an appropriate amount of miconazole nitrate from a portion of the Topical Powder to a suitable volumetric flask. Add *Diluent* equivalent to 50% of the flask volume, shake for 30 min, and sonicate for 10 min. Dilute with *Diluent* to volume. Pass a portion of the solution through a suitable filter of 0.45- μ m pore size.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 220 nm

Column: 4.6-mm \times 25-cm; 5- μ m packing [L7](#)

Column temperature: 32°**Flow rate:** See [Table 1](#).**Injection volume:** 5 µL**System suitability****Sample:** Standard solution**Suitability requirements****Tailing factor:** NMT 2.0**Relative standard deviation:** NMT 2.0%**Analysis****Samples:** Standard solution and Sample solutionCalculate the percentage of the labeled amount of miconazole nitrate ($C_{18}H_{14}Cl_4N_2O \cdot HNO_3$) in the portion of Topical Powder taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of miconazole from the Sample solution r_S = peak response of miconazole from the Standard solution C_S = concentration of [USP Miconazole Nitrate RS](#) in the Standard solution (mg/mL) C_U = nominal concentration of miconazole nitrate in the Sample solution (mg/mL)**Acceptance criteria:** 90.0%–110.0%**IMPURITIES**• **ORGANIC IMPURITIES****Buffer, Solution B, Solution C, Diluent, Standard stock solution, and Sample solution:** Prepare as directed in the Assay.**Solution A:** [Acetonitrile](#) and Buffer (35:65)**Mobile phase:** See [Table 2](#).**Table 2**

Time (min)	Solution A (%)	Solution B (%)	Solution C (%)	Flow rate (mL/min)
0	100	0	0	1.0
55.0	30.8	69.2	0	1.0
55.1	0	0	100	3.0
68.0	0	0	100	3.0
68.1	100	0	0	2.0
83.0	100	0	0	2.0
83.1	100	0	0	1.0
85.0	100	0	0	1.0

System suitability solution: 0.2 mg/mL of [USP Miconazole Nitrate RS](#) from the Standard stock solution and 0.2 µg/mL of [USP Miconazole Related Compound C RS](#) in Diluent**Standard solution:** 2 µg/mL of [USP Miconazole Nitrate RS](#) in Diluent from the Standard stock solution**Sensitivity solution:** 0.1 µg/mL of [USP Miconazole Nitrate RS](#) in Diluent from the Standard solution**Chromatographic system**(See [Chromatography \(621\), System Suitability](#).)**Mode:** LC**Detector:** UV 220 nm**Column:** 4.6-mm × 25-cm; 5-µm packing [L7](#)**Column temperature:** 32°**Flow rate:** See [Table 2](#).**Injection volume:** 15 µL**System suitability****Samples:** System suitability solution, Standard solution, and Sensitivity solution

Suitability requirements**Resolution:** NLT 1.5 between miconazole related compound C and miconazole, *System suitability solution***Relative standard deviation:** NMT 10.0%, *Standard solution***Signal-to-noise ratio:** NLT 10, *Sensitivity solution***Analysis****Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of miconazole related compound C and any individual unspecified degradation product in the portion of Topical Powder taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

 r_u = peak response of miconazole related compound C or any individual unspecified degradation product from the *Sample solution* r_s = peak response of miconazole from the *Standard solution* C_s = concentration of [USP Miconazole Nitrate RS](#) in the *Standard solution* ($\mu\text{g/mL}$) C_u = nominal concentration of miconazole nitrate in the *Sample solution* ($\mu\text{g/mL}$)**Acceptance criteria:** See [Table 3](#).**Table 3**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Miconazole	1.0	—
Miconazole related compound C	1.06	0.25
Any individual unspecified degradation product	—	0.10
Total impurities	—	1.0

PERFORMANCE TESTS

- [MINIMUM FILL \(755\)](#): Meets the requirements

SPECIFIC TESTS

- [MICROBIAL ENUMERATION TESTS \(61\)](#) and [TESTS FOR SPECIFIED MICROORGANISMS \(62\)](#): The total count does not exceed 10^2 cfu/g. It meets the requirements of the tests for the absence of *Staphylococcus aureus* and *Pseudomonas aeruginosa*.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers. Store at controlled room temperature.

Change to read:

- [USP REFERENCE STANDARDS \(11\)](#)

[USP Miconazole Nitrate RS](#)[USP Miconazole Related Compound C RS](#)2-[(2,4-Dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethan-1-amine Δ hydrochloride. $\text{C}_{15}\text{H}_{13}\text{Cl}_4\text{NO} \cdot \text{HCl}$ 401.53 Δ (ERR 1-Jun-2018)**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
MICONAZOLE NITRATE TOPICAL POWDER	Documentary Standards Support	SM12020 Small Molecules 1

Chromatographic Database Information: [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 43(2)

Current DocID: [GUID-7449DC06-7A1C-4862-BFF3-0166B2235825_6_en-US](#)

Previous DocID: [GUID-7449DC06-7A1C-4862-BFF3-0166B2235825_5_en-US](#)

DOI: https://doi.org/10.31003/USPNF_M54025_06_01

DOI ref: [z4t2j](#)

OFFICIAL